

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Hematology				
Hemophilia	Factor Xa	<p>Mouse studies suggest the factor XaI16L variant could be more effective than wild-type factor Xa at treating hemophilia. In mouse models of hemophilia A and B, human factor XaI16L had a 30- to 60-fold increase in half-life and lower clotting times compared with wild-type factor Xa. In these models, factor XaI16L decreased blood loss from a tail injury compared with wild-type factor Xa. Next steps include evaluating factor XaI16L in large animal models of hemophilia. Pfizer Inc's FXa-I16L is in preclinical development for hemophilia.</p> <p>SciBX 4(43); doi:10.1038/scibx.2011.1212 Published online Nov. 3, 2011</p>	Covered by multiple issued and pending patents; exclusively licensed to Pfizer	<p>Ivanciu, L. <i>et al. Nat. Biotechnol.</i>; published online Oct. 23, 2011; doi:10.1038/nbt.1995 Contact: Rodney M. Camire, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa. e-mail: rcamire@mail.med.upenn.edu</p>